Amedisys (AMED) Reiterated Buy At SunTrust After Investor Meetings
Tweet Send to a Friend
SunTrust analyst David MacDonald reiterated a Buy rating and $145.00 price target on Amedisys (NASDAQ: AMED) hosting management meetings for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
